We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioReference Laboratories, Inc., an OPKO Health company, is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the diagnosis of ...
BioReference Laboratories, Inc., an OPKO Health company, announced it will accept an Indefinite Delivery Indefinite Quantity (IDIQ) contract award to provide Commercial Surge Capacity Testing for COVID-19 Emergency Response to the CDC.
Miami-based Opko Health, Inc.’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the fourth quarter, compared to $147.7 million in the same period the year before.